Global Pharmacogenomics (PGx) Market Analysis: Focus on Ecosystem Players, Therapeutic Applications, and Geography – Estimation & Forecast 2016-2022

  • ID: 3651979
  • Report
  • Region: Global
  • 322 pages
  • BIS Research
1 of 6
The Global PGx Market Estimated to Grow Over $14.85 Billion by 2022

FEATURED COMPANIES

  • Abbott Laboratories
  • Affymetrix, Inc.
  • Assurex Health, Inc.
  • Astrazeneca
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • MORE
Global Pharmacogenomics (PGx) Market Analysis: Focus on Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others), and Geography – Estimation & Forecast 2016-2022

According to the meticulous report Global Pharmacogenomics (PGx) Market Analysis: Focus on Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others), and Geography – Estimation & Forecast 2016-2022, the global PGx market is expected to grow over $14.85 billion by 2022. An analyst at BIS Research states, “Rapid advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital Polymerase Chain Reaction (PCR) are developing a strong base for the growth of Pharmacogenomics (PGx) market.”

Rapid advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital Polymerase Chain Reaction (PCR) are developing a strong base for the growth of Pharmacogenomics (PGx) market. The completion of first human genome project in 1990s has created a platform for the development of further enhanced Pharmacogenomics solutions. PGx is not a modernized market yet, however, the increasing demand for precision medicine, targeted therapeutics and increasing cases of adverse drug reactions are some of the major factors which led to a tremendous growth rate in the past few years.

Since the announcement of ‘Precision Medicine Initiative’ by the President Barack Obama in January 2015, a large number of Research and Development (R&D) programs has been taken up for the developing precise drugs, targeted therapeutics, and laboratory tests which required Pharmacogenomics analysis. At present, government initiatives are focused towards launching a large number of PGx test & drugs, controlling the increasing level of genetic disorders, and integrating advanced technologies to fulfill the unmet needs of the patients. Most of the developments taking place in the present scenario are mainly related to oncology & cardiovascular diseases, but it is anticipated that it may target almost all therapeutic areas affected by genetic mutations.

Government regulations and standards are sustaining the growth and development of the PGx market. The main aim of these regulations is to make the PGx solutions more adaptable and focused toward oncology, pain management, central nervous system (CNS), Cardiovascular (CVD), and infectious diseases among others. The patients benefit indirectly from these regulations as it saves time and cuts down cost as the patients get the required treatment for the specific disease.

The market growth is propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorder/abnormalities, and government support and regulations.

This study includes an overview and analysis of the PGx market, by type of ecosystem players ,type of therapeutics application, technology type, and geographical regions; allowing the researcher to develop a comprehensive outlook of the market. The PGx market report presents a detailed analysis of the key market dynamics and provides an extensive insight into various forms of developments, trends and key participants. All of the above mentioned report coverage parameters are discussed across different regions like North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliances, and regulatory bodies, and their involvement in the PGx market. The research incorporates Porter’s Five Forces Model for in-depth analysis of the PGx market and an assessment of the factors governing it.

The answers to the following key questions can be found in the report:
- What are the major market drivers, challenges and opportunities of the PGx market and their use cases?
- What are the key trends and developments in the PGx market for genetic disease management?
- What are the key developmental strategies in different therapeutics across all regions?
- What are different types of PGx drugs and tests which are available in the market?
- How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launch among others?
- Which geographical region will lead the global PGx market by the end of the forecast period?
- Which different technologies are used to develop PGx solutions?
- Who are the key players in the PGx market?
- What are the government regulations for different PGx solutions?
- What are different types of therapeutics in PGx market and which type of PGx product used in their treatment?
- What is the different used case scenarios considered under different therapeutic applications?
- What are the PGx market trends and key developments in different geographical regions?

The research deals with various aspects of the PGx market such as factors driving the market, its threats that can possibly slow down the market growth and the current growth opportunities that are going to shape the market expansion of PGx solutions. The research incorporates Porter’s Five Forces Model for in-depth analysis of the PGx market and an assessment of the factors governing it. The report builds itself upon a comprehensive value chain giving a clear understanding of ecosystem of PGx market penetration.

Towards the end of the report, the readers will have a clear understanding of the market dynamics, major drivers and the underlying threats and challenges that the global PGx market is subjected to, including the estimation of the industry’s growth in terms of production and revenue.
The report includes the profiles of major players in the PGx market that allows the readers to gain an insight into the various industry trends.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • Affymetrix, Inc.
  • Assurex Health, Inc.
  • Astrazeneca
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • MORE
1. Report Overview
1.1. Report Scope
1.1.1. Report Coverage
1.1.2. Assumptions And Limitations
1.1.3. Market Classification & Segmentation
1.2. Research Methodology
1.2.1. Data Points Considered For Market Size Estimation
1.2.2. Key Data Point Sources
1.2.2.1. Key Data Points From Primary Sources
1.2.2.2. Key Data Points From Secondary Sources
1.2.3. Data Triangulation
1.2.4. Top-Down Approach
1.2.5. Bottom-Up Approach
1.3. Report Description

2. Executive Summary
2.1. Global Market Scenario

3. Market Overview
3.1. Introduction
3.2. Pharmacogenomics: Mechanism Of Action
3.3. Role Of Companion Diagnostics In Pgx
3.4. Role Of Biomarkers In Pgx
3.5. Role Of Molecular Diagnostics In Pgx
3.6. Benefits Of Pgx
3.7. End-Use Applications Of Pgx
3.8. Market Dynamics
3.8.1. Market Drivers
3.8.2. Market Challenges
3.8.3. Market Opportunities

4. Competitive Insights
4.1. Key Market Developments & Strategies
4.1.1. Competitive Landscape Of Some Of The Key Players
4.1.2. Partnerships, Joint Ventures And Collaborations
4.1.2.1. Key Insights
4.1.2.2. Recent Partnerships, Joint Ventures And Collaborations
4.1.3. Product Launch And Developments
4.1.3.1. Key Insights
4.1.3.2. Recent Product Launch And Developments
4.1.4. Patents, Licensing, Certification And Approvals
4.1.4.1. Key Insights
4.1.4.2. Recent Patents, Licensing, Certification And Approvals
4.1.5. Mergers And Acquisitions
4.1.5.1. Key Insights
4.1.5.2. Recent Mergers And Acquisitions
4.1.6. Business Contracts And Business Expansions
4.1.6.1. Key Insights
4.1.6.2. Recent Business Contracts And Business Expansions
4.1.7. Other Strategies
4.1.7.1. Key Insights
4.1.7.2. Recent Developmentts Of Other Strategies
4.2. Porter's Five Forces Analysis
4.2.1. Threat Of Substitutes
4.2.2. Threat Of New Entrants
4.2.3. Bargaining Power Of Buyers
4.2.4. Bargaining Power Of Suppliers
4.2.5. Intensity Of Competitive Rivalry

5. Industry Analysis
5.1. Patent Analysis
5.1.1. Some Of The Key Players
5.1.2. Others (University/Hospital/Person)
5.2. Regulations, Consortiums, Certifications, & Standards
5.2.1. Regulatory Bodies
5.2.2. Examples Of Some Common Acts Certifications
5.3. Value Chain Analysis

6. Global Pharmacogenomics Market By Technology
6.1. Market Segmentation By Technology
6.2. Microarray
6.2.1. Introduction
6.2.2. Microarray: Types, Applications & Key Players
6.2.3. Microarray: Market Dynamics & Recent Developments
6.3. Sequencing
6.3.1. Introduction
6.3.2. Sequencing: Market Dynamics, Applications & Key Players
6.3.3. Types Of Sequencing Technologies
6.3.3.1. Sanger Sequencing
6.3.3.2. Pyrosequencing
6.3.3.3. Next-Gen Sequencing (Ngs)
6.3.3.3.1. Next-Gen Sequencing (Ngs) Applications & Key Players
6.3.3.3.2. Next-Gen Sequencing (Ngs) Recent Developments
6.4. Polymerase Chain Reaction (Pcr)
6.4.1. Introduction
6.4.2. Pcr Types
6.4.3. Pcr: Market Dynamics, Applications & Key Players
6.5. Other Technologies
6.5.1. Mass Spectrometry
6.5.2. Electrophoresis

7. Global Pharmacogenomics Market By Ecosystem Players
7.1. Pgx Ecosystem Players: Overview
7.2. Market Segmentation By Ecosystem Players
7.2.1. Market Insights & Statistics
7.3. Diagnostic Test Companies
7.3.1. Introduction
7.3.2. Market Statistics
7.3.3. Diagnostic Companies: Drivers & Challenges
7.3.4. Recent Key Developments
7.3.5. Key Players
7.4. Pharmaceuticals Companies
7.4.1. Introduction
7.4.2. Market Statistics
7.4.3. Drug Development Process
7.4.4. Role Of Pharmaceutical Companies & Example Of Some Drugs
7.4.5. Pharmaceuticals Companies: Drivers & Challenges
7.4.6. Recent Key Developments
7.4.7. Key Players
7.5. Service Providers
7.5.1. Introduction
7.5.2. Market Statistics
7.5.3. Service Provider: Roles & Big Data Benefits
7.5.4. Big Data Companies: Drivers & Challenges
7.5.5. Recent Key Developments
7.5.6. Key Players

8. Global Pharmacogenomics Market By Therapeutic Applications
8.1. Market Segmentation
8.2. Market Statistics
8.3. Cancer/Oncology
8.3.1. Key Insights & Statistics
8.3.2. Market Statistics
8.3.3. Types Of Cancer
8.3.4. Cancer: Examples Of Some Drugs
8.3.5. Cancer: Examples Of Some Tests
8.3.6. Market Dynamics & Key Players
8.3.7. Recent Key Developments
8.4. Cardiovascular Diseases (Cvd)
8.4.1. Key Insights & Statistics
8.4.2. Market Statistics
8.4.3. Cvd: Examples Of Some Drugs
8.4.4. Cvd: Examples Of Some Tests
8.4.5. Recent Key Developments & Key Players
8.5. Central Nervous System (Cns)
8.5.1. Key Insights & Statistics
8.5.2. Market Statistics
8.5.3. Cns: Examples Of Some Drugs
8.5.4. Cns: Examples Of Some Tests
8.5.5. Recent Key Developments & Key Players
8.6. Infectious Diseases
8.6.1. Key Insights & Statistics
8.6.2. Market Statistics
8.6.3. Infectious Diseases: Examples Of Some Drugs
8.6.4. Recent Key Developments & Key Players
8.7. Other Diseases
8.7.1. Key Insights & Statistics
8.7.2. Market Statistics
8.7.3. Other Diseases: Examples Of Some Drugs
8.7.4. Other Diseases: Examples Of Some Tests
8.7.5. Recent Key Developments & Key Players

9. Global Pharmacogenomics Market By Geography
9.1. Geographical Scenario
9.2. Market Insights & Statistics
9.3. North America
9.3.1. Market Scope
9.3.2. North America: Market Insights & Statistics
9.3.3. North American Market Dynamics
9.3.4. Key Regulatory Bodies & Associations
9.3.5. The U.S.
9.3.5.1. The U.S.: Market Statistics
9.3.5.2. The U.S.: Key Insights
9.3.6. Canada
9.3.7. Recent Key Developments
9.4. Europe
9.4.1. Market Scope
9.4.2. Europe: Market Insights & Statistics
9.4.3. European Market Dynamics
9.4.4. Key Regulatory Bodies & Associations
9.4.5. The U.K.
9.4.6. Germany
9.4.7. Recent Key Developments
9.5. Asia-Pacific (Apac)
9.5.1. Market Scope
9.5.2. Apac: Market Insights & Statistics
9.5.3. Apac Market Dynamics
9.5.4. China
9.5.5. Japan
9.5.6. India
9.5.7. Recent Key Developments
9.6. Rest Of The World (Row)
9.6.1. Row: Market Insights & Statistics
9.6.2. Middle East
9.6.3. South America
9.6.4. Africa
9.6.5. Recent Key Development

10. Company Overview
10.1. Abbott Laboratories
10.1.1. Overview
10.1.2. Financials
10.1.3. Financial Summary
10.1.4. Key Developments
10.1.5. Swot Analysis
10.2. Affymetrix, Inc.
10.2.1. Overview
10.2.2. Financials
10.2.3. Financial Summary
10.2.4. Key Developments
10.2.5. Swot Analysis
10.3. Assurex Health, Inc.
10.3.1. Overview
10.3.2. Key Developments
10.3.3. Swot Analysis
10.4. Astrazeneca
10.4.1. Overview
10.4.2. Financials
10.4.3. Financial Summary
10.4.4. Key Developments
10.4.5. Swot Analysis
10.5. Illumina, Inc.
10.5.1. Overview
10.5.2. Financials
10.5.3. Financial Summary
10.5.4. Key Developments
10.5.5. Swot Analysis
10.6. Laboratory Corporation Of America Holdings
10.6.1. Overview
10.6.2. Financials & Financial Summary
10.6.3. Key Developments
10.6.4. Swot Analysis
10.7. Myriad Genetics, Inc.
10.7.1. Overview
10.7.2. Financials & Financial Summary
10.7.3. Key Developments
10.7.4. Swot Analysis
10.8. Pfizer, Inc.
10.8.1. Overview
10.8.2. Financials
10.8.3. Financial Summary
10.8.4. Key Developments
10.8.5. Swot Analysis
10.9. Qiagen, Inc.
10.9.1. Overview
10.9.2. Financials
10.9.3. Financial Summary
10.9.4. Key Developments
10.9.5. Swot Analysis
10.1o Roche Holding Ag-Br
10.10.1. Overview
10.10.2. Financials
10.10.3. Financial Summary
10.10.4. Key Developments
10.10.5. Swot Analysis
10.11. Teva Pharmaceutical Industries Ltd.
10.11.1. Overview
10.11.2. Financials
10.11.3. Financial Summary
10.11.4. Key Developments
10.11.5. Swot Analysis
10.12. Thermo Fisher Scientific
10.12.1. Overview
10.12.2. Financials
10.12.3. Financial Summary
10.12.4. Key Developments
10.12.5. Swot Analysis
10.13. Transgenomic, Inc.
10.13.1. Overview
10.13.2. Financials & Financial Summary
10.13.3. Key Developments
10.13.4. Swot Analysis
10.14. Other Emerging Companies
10.14.1. Diagnostic Test Companies
10.14.1.1. Companiondx Reference Lab, Llc
10.14.1.2. Mapmy Genome
10.14.1.3. Asuragen
10.14.1.4. 23andme
10.14.1.5. Cnsdose
10.14.2. Pharmaceutical Companies
10.14.2.1. Actinium Pharmaceuticals, Inc
10.14.2.2. Foundation Medicine
10.14.3. Service Providers
10.14.3.1. Pgx Software Llc
10.14.3.2. Gene Logic
10.14.3.3. Genewiz
10.14.3.4. Conatus Consulting, Llc
10.14.4. Care Providers
10.14.4.1. Gene Dx
10.14.4.2. Mayo Clinic

11. List Of Acronyms

List Of Figures
Year Consideration
Market Classification & Segmentation
Research Methodology
Global Pharmacogenomics Market ($Billion)
Global Pharmacogenomics Market Value, 2015-2022 ($Billion)
Global Pgx Market, By Ecosystem, 2015-2022 ($Billion)
Global Pgx Market Share, By Therapeutic Application, 2015-2022 ($Billion)
Global Pharmacogenomics Market, By Geography-2022
Mechanism Of Action
Role Of Companion Diagnostics In Pgx
Role Of Biomakers In Pgx
Role Of Molecular Diagnostics In Pgx
Benefits Of Pgx
End-Use Applications Of Pgx
Market Dynamics
Partnerships, Joint Ventures And Collaborations: Key Players Analysis
Product Launch And Developments: Key Players Analysis
Patents, Licensing, Certification And Approvals: Key Players Analysis
Mergers And Acquisitions: Key Players Analysis
Business Contracts And Business Expansions: Key Players Analysis
Others Strategies: Key Players Analysis
Porter's Five Forces Analysis
Threat Of Substitutes
Threat Of New Entrants
Bargaining Power Of Buyers
Bargaining Power Of Suppliers
Intensity Of Competitive Rivalry
Roles And Responsibilities Of Healthcare Policy Makers
Role Of Fda In Pgx
Classification Of Medical Devices
Examples Of Some Common Acts
Example Of Some Certifications
Value Chain Analysis
Example Of Some Significant Players In Pgx Value Chain
Generalized Process For The Microarray
Different Types Of Microarrays
Applications Of Microarrays
Microarray- Drivers & Challenges
Sequencing Technologies In Pgx
Sequencing - Drivers & Challenges
Applications Of Sequencing
Ngs- Drivers & Challenges
Applications Of Ngs
Generalized Process For Pcr
Different Types Of Pcr
Pcr - Drivers & Challenges
Applications Of Pcr
Applications Of Mass Spectrometry
Applications Of Electrophoresis
Overview Of Pgx Ecosystem Players
Global Pgx Market By Ecosystem Players
Global Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion)
Global Pgx Ecosystem Market, By Diagnostic Tests Companies, 2015-2022 ($Billion)
Global Pgx Diagnostic Tests Market, By Therapeutic Applications, 2015-2022 ($Billion)
Global Pgx Diagnostic Tests Market, By Geography, 2015-2022 ($Billion)
Diagnostic Companies- Drivers & Challenges
Global Pgx Ecosystem Market, By Pharmaceutical Companies, 2015-2022 ($Billion)
Global Pgx Pharmaceutical Market, By Therapeutic Applications, 2015-2022 ($Billion)
Global Pgx Pharmaceutical Market, By Geography, 2015-2022 ($Billion)
Drug Development Process
Role Of Pharmaceuticals Companies
Pharmaceuticals Companies- Drivers & Challenges
Global Pgx Ecosystem Market, By Service Providers, 2015-2022 ($Billion)
Global Pgx Service Providers Market, By Therapeutic Applications, 2015-2022 ($Billion)
Global Pgx Service Providers Market, By Geography, 2015-2022 ($Billion)
Three Data Drivers Of Pgx Market
Benefits Of Big Data
Big Data Companies- Drivers & Challenges
Global Pgx Market By Therapeutics Applications
Global Pgx Market, By Theraeutics Application, 2015-2022 ($Billion)
Global Pgx Market By Oncology, 2015-2022($Billion)
Global Pgx Oncology Market, By Ecosystem, 2015-2022 ($Billion)
Global Pgx Oncology Market, By Geography, 2015-2022 ($Billion)
Types Of Cancer
Oncology Market Dynamics
Global Pgx Market By Cvd, 2015-2022 ($Billion)
Global Pgx Cvd Market, By Ecosystem, 2015-2022 ($Billion)
Global Pgx Cvd Market, By Geography, 2015-2022 ($Billion)
Global Pgx Market By Cns, 2015-2022 ($Billion)
Global Pgx Cns Market, By Ecosystem, 2015-2022 ($Billion)
Global Pgx Cns Market, By Geography, 2015-2022 ($Billion)
Global Pgx Market By Infectious Diseases, 2015-2022 ($Billion)
Global Pgx Infectious Diseases Market, By Ecosystem, 2015-2022 ($Billion)
Global Pgx Infectious Diseases Market, By Geography, 2015-2022 ($Billion)
Global Pgx Market By Other Diseases, 2015-2022 ($Billion)
Global Pgx Other Diseases Market, By Ecosystem, 2015-2022 ($Billion)
Global Pgx Other Diseases Market, By Geography, 2015-2022 ($Billion)
Growth Trajectory Of Pgx Market
Global Pharmacogenomics Market, By Geography, 2015-2022 ($Billion)
Global Pharmacogenomics Market, By Geography (2015)
North American Pgx Market, 2015
North American Pgx Market, 2015-2022 ($Billion)
North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
North American Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion)
North American Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion)
North American Market Dynamics
Key Regulatory Bodies & Associations
The U.S. Pgx Market, 2015-2022 ($Billion)
The U.S. Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion)
The U.S. Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion)
Canada Pgx Market Dynamics
European Pgx Market, 2015
European Pgx Market, 2015-2022($Billion)
European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
European Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion)
European Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion)
European Market Dynamics
Key Regulatory Bodies & Associations
The U.K. Pgx Market, 2015-2022 ($Billion)
The Germany Pgx Market, 2015-2022 ($Billion)
Apac Country-Wise Cagr Of Pgx Market
Apac Pgx Market, 2015-2022 ($Billion)
Apac Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
Apac Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion)
Apac Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion)
Apac Market Dynamics
The China Pgx Market, 2015-2022 ($Billion)
China Market Dynamics
The Japan Pgx Market, 2015-2022 ($Billion)
The Indian Pgx Market, 2015-2022 ($Billion)
Indian Market Dynamics
Region-Wise Cagr Of Pgx Market
Row Pgx Market, 2015-2022 ($Billion)
Row Pgx Market, By Sub-Region, 2015-2022 ($Billion)
Row Pgx Market, By Ecosystem, 2015-2022 ($Billion)
Row Pgx Market, By Therapeutics, 2015-2022 ($Billion)
Middle East Pgx Market, 2015-2022 ($Billion)
South American Pgx Market, 2015-2022 ($Billion)
African Pgx Market, 2015-2022 ($Billion)
Abbott Laboratories, Inc. - Overall Financials, 2013-2015 ($Billion)
Abbott Laboratories, Inc. - Financials By Business Segments, 2013-2015 ($Billion)
Abbott Laboratories, Inc. - Financials By Geography, 2013-2015 ($Billion)
Abbott Laboratories, Inc. - Swot Analysis
Affymetrix, Inc. - Overall Financials, 2013-2015 ($Million)
Affymetrix, Inc. - Financials By Business Segments, 2013-2015 ($Million)
Affymetrix, Inc. - Financials By Geography, 2013-2015 ($Million)
Affymetrix, Inc. - Swot Analysis
Assurex Health, Inc. - Swot Analysis
Astrazeneca - Overall Financials, 2013-2015 ($Billion)
Astrazeneca- Financials By Business Segments, 2013-2015 ($Billion)
Astrazeneca- Financials By Geography, 2013-2015 ($Billion)
Astrazeneca- Swot Analysis
Illumina, Inc. - Overall Financials, 2013-2015 ($Million)
Illumina, Inc. - Financials By Business Segments, 2013-2015 ($Million)
Illumina, Inc. - Financials By Geography, 2013-2015 ($Million)
Illumina, Inc. - Swot Analysis
Laboratory Corporation Of America Holding. - Overall Financials, 2013-2015 ($Million)
Laboratory Corporation Of America Holding-Financials By Business Segments, 2013-2015 ($ Million)
Laboratory Corporation Of America Holding. - Swot Analysis
Myriad Genetics, Inc. - Overall Financials, 2013-2015 ($Million)
Myriad Genetics, Inc. - Financials By Business Segments, 2013-2015 ($Million)
Myriad Genetics, Inc. - Swot Analysis
Pfizer, Inc. - Overall Financials, 2013-2015 ($Billion)
Pfizer, Inc. - Financials By Geography, 2013-2015 ($Billion)
Pfizer, Inc. - Financials By Business Segments, 2014-2015 ($Billion)
Pfizer, Inc. - Financials By Business Segment, 2013
Pfizer, Inc. - Swot Analysis
Qiagen- Overall Financials, 2013-2015 ($Million)
Qiagen- Financials By Business Segments, 2013-2015 ($Million)
Qiagen- Financials By Geography, 2013-2015 ($Million)
Qiagen- Swot Analysis
Roche Holding- Overall Financials, 2013-2015 ($Billion)
Roche Holding- Financials By Business Segments, 2013-2015 ($Billion)
Roche Holding- Financials Of Diagnostics Division By Geography, 2013-2015 ($Billion)
Roche Holding- Financials Of Pharmaceuticals, Segment By Geography, 2013-2015 ($Billion)
Roche Holding- Swot Analysis
Teva Pharmaceutical Ltd. - Overall Financials, 2013-2015 ($Billion)
Teva Pharmaceutical Ltd. - Financials By Business Segments, 2013-2015 ($Billion)
Teva Pharmaceutical Ltd. - Financials By Geography, 2013-2015 ($Billion)
Teva Pharmaceutical Industries Ltd. - Swot Analysis
Thermo Fisher, Inc. - Overall Financials, 2013-2015 ($Billion)
Thermo Fisher, Inc. - Financials By Business Segments, 2013-2015 ($Billion)
Thermo Fisher, Inc. - Financials By Geography, 2013-2015 ($Billion)
Thermo Fisher Scientific, Inc. - Swot Analysis
Transgenomic, Inc. - Overall Financials, 2013-2015 ($Million)
Transgenomic, Inc. - Financials By Business Segements, 2013-2015 ($Million)
Transgenomic, Inc. - Swot Analysis

List Of Tables
Competitive Landscape: Some Of The Key Players
Recent Partnerships, Joint Ventures And Collaborations
Recent Product Launch And Developments
Recent Patents, Licensing, Certification And Approvals
Recent Mergers And Acquisitions
Recent Business Contracts And Business Expansions
Recent Developmentts Of Other Strategies
Patent Analysis Of Some Key Players
Patent Analysis Of Some University/Hospital/Person
Microarray- Recent Key Developments
Ngs- Recent Key Developments
Difference Between Realt Time & Digital Pcr
Diagnostic Test Companies- Recent Key Developments
Example Of Some Pharmacogenomic Drugs
Pharmaceuticals Companies- Recent Key Developments
Service Providers- Recent Key Developments
Cancer- Examples Of Some Drugs
Cancer- Examples Of Some Tests
Oncology- Recent Key Developments
Cvd- Examples Of Some Drugs
Cvd- Examples Of Some Tests
Cns- Examples Of Some Drugs
Cns- Examples Of Some Tests
Infectious Diseases- Examples Of Some Drugs
Other Diseases- Examples Of Some Drugs
North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
North American Pharmacogenomics Market Recent Key Dvelopments
European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
European Pgx Market Recent Key Developments
Apac Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
Apac Pharmacogenomics Market Recent Key Developments
Row Pharmacogenomics Market, By Sub-Region, 2015-2022
Row Recent Key Development
Abbott Laboratories, Inc. Recent Developments
Affymetrix, Inc. Recent Developments
Assurex Health, Inc. Recent Developments
Astrazeneca Recent Developments
Illumina, Inc. Recent Developments
Laboratory Corporation Of America Holding Recent Developments
Myriad Genetics Recent Developments
Pfizer, Inc. Recent Developments
Qiagen Recent Developments
Roche Holding Recent Developments
Teva Pharmaceutical Industries Ltd. Recent Developments
Thermo Fisher, Inc. Recent Developments
Transgenomic, Inc. Recent Developments

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • Affymetrix, Inc.
  • Assurex Health, Inc.
  • Astrazeneca
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • MORE
The global Pharmacogenomics (PGx) market growth is gradually gaining speed as large number of government initiatives and research & development programs have been launched in the last few years. Advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital PCR are developing the platform for the growth of Pharmacogenomics (PGx) market. The global PGx market is expected to grow over $14.85 billion by 2022. The market growth is propelling due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorders/abnormalities, and government support and regulations.

The report has been further classified on the basis of ecosystem players, therapeutic applications, and geographical regions. Ecosystem is further segmented into: Pharmaceuticals companies, Diagnostic Companies, and Service Providers, which include Software & Healthcare database providers, Hospitals & Care Providers, and Insurance Providers.

Diagnostic Test segment is holding the maximum market share and is expected to grow at 11.63% CAGR from 2016 to 2022. This is due to the increasing demand for diagnostic tests as patients are emphasizing more on pre-diagnosis treatments, increasing genetic disorders & mutational diseases, and government initiatives and investment in research and development programs among others.

Observing current trends, Big Data companies included in service provider segments are collaborating and entering into partnerships with healthcare providers, academic institutions, pharmaceuticals and biotechnology companies to support the growth of the PGx market and thus, service segment is anticipated to grow at a high CAGR of 16.22% from 2016 to 2022. Moreover, the Pharmaceutical segment will also gain from traction of the patients due to increasing awareness about the benefits of PGx solutions and adoption of these solutions in developing regions.

With the increasing research and development process, it has been estimated that the demand for precision drugs will escalate in the coming future
and thus result in the high growth of pharmaceutical & biotech companies.

The global PGx market on the basis of therapeutics is classified as cancer, cardiovascular, central nervous system, infectious diseases and other diseases. At present, Cancer is dominating the market and is expected to grow at a CAGR of 12.23% from 2016 to 2022, as the cases of cancer patients are increasing every year and thus, deployment of targeted therapeutics and diagnosis applications of cancer is also anticipated to increase tremendously.

The primarily reason attributed to the growth of the therapeutics market is due to the increase in cancer cases, cardiac diseases, skin diseases, HIV, mental disorders , and other genetic disorders. However, the infectious diseases are gaining more traction as compared to other diseases as the numbers of patients suffering from these diseases are increasing at a very rapid growth rate all over the world specifically in African and Asian countries. This segment is growing at a CAGR of 17.49% from 2016 to 2022.

In North America, existing players are integrating with new start-ups through partnerships and collaborations to capture the North American segment. North American local players are entering in other developing regions to acquire larger market share. Throughout the Asia-Pacific and European countries, regulatory bodies are rolling out regulations to keep a check on latest technologies.

North America is the largest contributor in the revenue generation in PGx market followed by Europe region, and is expected to grow at a high CAGR of 12.14% CAGR from 2016 to 2022. APAC region is expected to show the fastest growth globally, and is expected to grow at 18.74% CAGR from 2016 to 2022.

The APAC region is focusing more on technological development and introduction of new gene sequencing and gene mapping tools into healthcare systems to develop specific laboratory diagnostic tests.

Note: Product cover images may vary from those shown
5 of 6
- Abbott Laboratories
- Affymetrix, Inc.
- Assurex Health, Inc.
- Astrazeneca
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- Myriad Genetics, Inc.
- Pfizer, Inc.
- Qiagen, Inc.
- Roche Holding Ag-Br
- Teva Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific
- Transgenomic, Inc.

Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll